Pax

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Pax

What is Pax? Definition and Pharmacological Classification

Property Description
Active Ingredient Diazepam
Form Tablet, Solution (Injectable/Oral), Rectal Gel, Nasal Spray
Pharmacological Class Benzodiazepine, CNS Depressant
Common Use Anxiolytic, Anticonvulsant, Muscle Relaxant
Origin Synthetic

Pax is a common trade name for the medication containing the single active ingredient, Diazepam, which is chemically defined as a synthetic compound and belongs to the Benzodiazepine (BDZ) class. This classification designates it as a Central Nervous System (CNS) Depressant, a fundamental property recognized for its ability to reduce nervous system hyperactivity. As a long-acting BDZ, Diazepam is distinguished by its sustained duration of effect. It is classified as a Schedule IV controlled substance, reflecting its potential for dependence and the necessity for regulated clinical oversight. Its presence on the Model List of Essential Medicines further affirms its role in managing acute neurological and psychological states globally.


Composition and Available Pharmaceutical Forms

The core therapeutic component is Diazepam, confirming Pax as a single-ingredient drug. This active substance is incorporated into multiple distinct pharmaceutical preparations to ensure flexibility in patient care. The most common form is the solid tablet for the oral route. However, the availability of forms such as solutions for intravenous (IV) and intramuscular (IM) injection, as well as specialized forms like the rectal gel and nasal spray, is a key differentiating feature. This variety allows healthcare providers to select the appropriate route of administration when rapid effect is required or when oral administration is not possible.


General Purpose and Primary Physiological Effect

The general purpose of Pax is to induce a controlled calming effect by stabilizing the nervous system, addressing conditions characterized by excessive neuronal excitation. The medication's physiological impact enables it to serve as an effective antianxiety (anxiolytic) agent to relieve severe nervousness, an anticonvulsant to manage abnormal brain electrical activity, and a skeletal muscle relaxant to alleviate intense muscular tension. The medicine is commonly used to manage acute, temporary states, such as the agitation associated with severe alcohol withdrawal.

Regulatory References

  1. NIH information on Diazepam
  2. WHO Model List of Essential Medicines

What side effects are possible with Pax?

Possible Side Effects and Safety Information

The safety profile for Pax (Diazepam) is documented in official regulatory labeling and primarily reflects its core function as a Central Nervous System (CNS) Depressant. Adverse effects are classified by frequency and System Organ Class (SOC) according to governmental regulatory documents.


Documented Adverse Reactions and Frequencies

Classification System-Organ-Class Documented Reactions
Common / Most Common Nervous System / General Disorders Somnolence (drowsiness), fatigue, ataxia (impaired coordination), confusion, muscle weakness, slurred speech.
Rare Immune System Disorders Anaphylaxis (severe allergic reaction).

Serious Safety Concerns and Constraints

Official labeling emphasizes several serious safety concerns. Respiratory depression and profound sedation, potentially leading to coma or death, are noted as critical risks, especially when Pax is used concomitantly with opioids or other strong CNS depressants. The risk of developing physical dependence and severe withdrawal symptoms is officially associated with sustained, long-term use. The medication is officially restricted (contraindicated) in patients with severe hepatic insufficiency, severe respiratory insufficiency, and myasthenia gravis.

Population-Specific Safety Notes

Safety notes specify that older adults and debilitated patients may exhibit increased sensitivity to the CNS effects, such as confusion and unsteadiness. Use is officially restricted in infants under six months of age. Furthermore, use during the late stages of pregnancy carries a documented risk of non-teratogenic effects in the neonate, including flaccidity and hypothermia.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose involving Pax (Diazepam) is officially documented by regulatory sources as a consequence of the drug’s Central Nervous System (CNS) depressant activity. Manifestations are described along a continuum of severity, starting with symptoms such as drowsiness, ataxia (uncoordinated movement), slurred speech, and diminished reflexes. The most severe, life-threatening outcomes are associated with profound CNS and respiratory suppression. These include severe respiratory depression, hypotension (low blood pressure), coma, and the risk of respiratory arrest. This severity is notably compounded when the medication is co-ingested with other CNS depressants, such as opioids or alcohol.

Mandatory Emergency Action

Regulatory guidance explicitly states that a person must seek immediate medical help upon suspicion of overdose. Urgent medical attention is required, and emergency services must be contacted, if the individual experiences slowed or difficult breathing, seizure, or is unable to respond or wake up.

Management procedures involve supportive care as the primary intervention, including continuous vital signs monitoring and the administration of intravenous fluids. The specific competitive benzodiazepine antagonist Flumazenil is available for use, though its administration is noted to carry the risk of precipitating acute withdrawal reactions. Special caution is also noted for the elderly and those with limited pulmonary function due to increased risk of complications like apnea.

Therapeutic Uses of Pax

What Pax Treats: Main Uses and Benefits

Pax is relevant for providing supportive symptomatic relief across clinical domains marked by nervous system hyper-excitation. It is commonly used when symptoms that interfere with daily functioning are acute, severe, or significantly disruptive, contributing to easing the overall symptom burden. This medication is utilized in the therapeutic areas of symptomatic anxiety, acute seizures, muscle spasms, and severe alcohol withdrawal.

This medication helps address symptom clusters that may become intense or disruptive in conditions characterized by periods of heightened symptoms. For instance, in managing severe anxiety, it helps ease overwhelming apprehension and physical restlessness. In neurological contexts, it is commonly used to help with controlling or interrupting ongoing or clustered seizure activity, which is consistent with conditions presenting with acute episodes.

“This use offers symptomatic assistance that supports patients during episodes of heightened discomfort and temporary symptom stabilization.”

The medication also assists in managing the symptoms of involuntary skeletal muscle spasms and rigidity, which contributes to improved day-to-day comfort during symptomatic periods by easing the impact of severe muscle tension on mobility and general functioning. It is relevant in contexts involving heightened systemic burden, such as stabilizing patients during the acute stages of alcohol withdrawal syndrome by moderating distressing manifestations like severe tremors and agitation.


Quick Fact: Relief for Neurological and Muscular Hyperactivity

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility and Contraindication Status

The use of Pax (diazepam) is strictly defined by regulatory documents, which establish absolute contraindications and population-specific restrictions.

Category Official Regulatory Status
Contraindicated Populations Patients with known hypersensitivity, Myasthenia Gravis, Severe Hepatic Insufficiency, Severe Respiratory Insufficiency, Sleep Apnea Syndrome, and Acute Narrow-Angle Glaucoma must not use this medicine.
Age-Based Eligibility Contraindicated in infants under 6 months of age for oral forms. Use is allowed in adults, but a reduced dose is recommended for older adults (65+ years).
Condition-Specific Rules Use is contraindicated in Severe Hepatic Insufficiency. Patients with Chronic Hepatic Disease require a reduced dose. Use in patients with Chronic Respiratory Insufficiency also requires a lower dose.
Pregnancy and Lactation Use during pregnancy and lactation is generally not recommended unless the clinical situation warrants the potential risk.

Eligibility is further restricted in patients with a history of alcohol or drug abuse and those with depression, where the medicine should not be used alone. Regulatory documents prohibit the use of this medicine as a primary treatment for Psychotic Illness.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The regulatory profile for Pax (Diazepam) defines interaction patterns primarily through its metabolism and its effect on the central nervous system (CNS). These documented patterns dictate specific co-administration restrictions and cautions listed in official government prescribing information.


Documented Interaction Patterns

Interaction Domain Practical Implication (Official Regulatory Statement)
Additive CNS Depression Opioids and other CNS-depressing drugs (e.g., Barbiturates, Antipsychotics) must be used with extreme caution, as this combination is officially associated with an increased risk of profound sedation and respiratory depression.
Metabolic Inhibition/Induction Substances that inhibit CYP2C19 and CYP3A4 enzymes (e.g., Omeprazole, Fluoxetine) are documented to increase Pax exposure by decreasing its clearance. Conversely, enzyme-inducing substances (e.g., Carbamazepine) are documented to decrease exposure.
Consumption-Related Interaction Ingestion of Alcohol must be avoided as it exacerbates CNS depressant effects. Grapefruit products may also increase systemic exposure. Absorption is documented to be delayed when taken with a moderate fat meal.

Official statements establish prohibitions and explicit cautions for co-administration. The drug is contraindicated in severe hepatic insufficiency due to the liver's role in drug metabolism, and the risk of interaction, including enhanced sedation, is officially noted as increased in elderly patients compared to younger populations.

Mechanism of Action

The mechanism of Diazepam (Pax) operates entirely within the central nervous system ( CNS), focusing on the potentiation of inhibitory signaling to modify neuronal circuit activity.

Molecular Potentiation of GABA A Receptor

The drug’s primary biological target is the GABA A receptor complex. Diazepam acts as a positive allosteric modulator, binding to a site distinct from the gamma-aminobutyric acid ( GABA) binding site to enhance GABA's inhibitory effect. This action increases the frequency of chloride ( Cl^-) ion channel opening, driving the neuron into a state of hyperpolarization and reducing its excitability. This forms the cellular basis for subsequent system-wide inhibitory effects.

Systemic Modulation of Neural Circuits

This domain describes the effect of enhanced inhibition across key CNS pathways, including the limbic system and the cerebral cortex. By increasing inhibitory tone, the mechanism reduces the rapid, synchronized firing of neurons across these circuits, leading to a systemic reduction of neurological excitability.

Central Modulation of Skeletal Muscle Tone

This domain addresses the drug’s impact on spinal reflex arcs. The enhanced inhibition affects interneurons in the spinal cord, interrupting the feedback loop that maintains excessive muscle contraction, which produces a centrally mediated reduction in skeletal muscle tone and contributing directly to the physiological consequence of reduced skeletal muscle tension.

Dosage and Administration Information

Pax (Diazepam) is used according to specific protocols that define the method, frequency, and duration of its administration.

Administration Routes and Standard Regimens

The medicine is indicated for delivery via multiple routes, including oral (as tablets or liquid solution), intravenous (IV), intramuscular (IM), rectal (gel/solution), and intranasal spray. The choice of route is determined by the clinical need for rapid onset versus routine management.

For chronic oral use in adults, standard regimens typically involve a dose range of 2 mg to 10 mg, administered in divided doses two to four times daily. For urgent situations like status epilepticus, the IV dose should not exceed a cumulative maximum of 30 mg, and the injection must be administered slowly at a rate not exceeding 5 mg per minute. The IV solution must not be diluted or mixed with other solutions.

Duration and Population Adjustments

Treatment duration is generally subject to specific constraints: use for anxiety symptoms is short-term, generally not exceeding two to four weeks, which includes the necessary dose tapering. Furthermore, specialized forms for acute intermittent seizures (rectal and nasal) have frequency limits, allowing a maximum of one treated episode every five days.

Dosage modification is required for specific groups: older or debilitated patients typically begin with a reduced initial dose of 2 mg to 2.5 mg once or twice daily, and oral administration is not indicated in children under six months of age.

Recent Clinical Evidence

Clinical trial evidence has established Pax as an effective oral antiviral treatment for mild-to-moderate COVID-19 in patients at high risk for progression to severe illness, including hospitalization or death. The pivotal Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) study demonstrated significant efficacy when the treatment was initiated within five days of symptom onset.

Efficacy in High-Risk Patients

In the EPIC-HR trial, which focused on unvaccinated high-risk adults, Paxlovid achieved a substantial relative risk reduction in COVID-19-related hospitalization or death from any cause through Day 28, compared to placebo. Key findings included:

  • 88% relative risk reduction when treatment was initiated within five days of symptom onset.
  • In this high-risk population, the rate of hospitalization or death was 0.8% in the Paxlovid group versus 6.5% in the placebo group when treatment was started within five days. No deaths were reported in the Paxlovid treatment arm through the study's primary endpoint period.

Real-world observational studies conducted during the dominance of the Omicron variant have generally corroborated these findings, particularly in older adults and those with multiple underlying health conditions, suggesting the drug maintains a protective effect in diverse patient populations, including those who are vaccinated or previously infected.

Safety and Adverse Events

Safety data across clinical trials show that Paxlovid is generally well-tolerated. Treatment-emergent adverse events were comparable between the Paxlovid and placebo groups, with most being mild in intensity. The most commonly reported side effects included dysgeusia (a change in taste, often described as metallic) and diarrhea.

Potential risks include a complex network of drug-drug interactions due to the ritonavir component, which can affect the metabolism of many commonly prescribed medications. Caution is also advised when prescribing to patients with pre-existing liver conditions due to a risk of hepatotoxicity associated with ritonavir. For patients with moderate to severe kidney impairment, a dose adjustment is necessary to prevent accumulation of the active antiviral component.

Frequently Asked Questions (FAQ)

Common questions about Pax (FAQ)


Q: What happens if I stop taking Pax suddenly?

Regulatory warnings indicate that stopping Pax abruptly after a period of regular use is associated with a risk of developing severe withdrawal symptoms. Regulatory warnings indicate this is a risk and caution against abrupt discontinuation due to the potential for serious effects, such as seizures or a return of anxiety symptoms.


Q: Does Pax interact with common over-the-counter pain relievers?

Official drug information prioritizes interactions with medications that cause CNS depression or that affect the way Pax is processed by the body’s enzymes. There is no specific warning listed in regulatory documents regarding common non-opioid pain relievers like acetaminophen or ibuprofen.


Q: Can Pax be taken with common dietary supplements like vitamins?

Official documents caution against using Pax with products that enhance CNS depressant effects or affect the drug's metabolism, such as alcohol or grapefruit products. However, there is no specific information provided in general patient labeling regarding standard multivitamin supplements.


Q: What is the difference between Pax and other medicines that treat the same condition?

The official classification of Pax (Diazepam) is that of a long-acting Benzodiazepine. This pharmacological feature is a key characteristic noted in the drug's official classification, reflecting a sustained duration of effect.


Q: Can Pax interact with birth control pills?

Regulatory documents indicate that drugs which affect certain liver enzymes (specifically CYP3A4 or CYP2C19) may change how the body processes Pax. The full extent of interactions with specific types of oral contraceptives is not always detailed in the general patient information.


Q: Does Pax cause dependence or withdrawal symptoms?

Official labeling explicitly highlights the serious safety concern that prolonged, sustained use of Pax is associated with the risk of developing physical dependence and experiencing severe withdrawal symptoms if the medication is stopped abruptly.


Q: Can Pax be taken on an empty stomach?

According to the official prescribing information, taking Pax with a moderate fat meal is documented to delay the absorption of the drug and slightly decrease its effectiveness. Taking it with a moderate fat meal decreases the absorption rate and delays the time to peak concentration compared to a fasted state.


Q: What happens if I take too much Pax?

Taking excessive amounts of Pax can result in symptoms of severe Central Nervous System (CNS) depression. This may result in significant CNS depression, including profound sedation, respiratory depression, and coma.


Q: Can Pax be split or crushed?

Patient-facing guidance often advises users to swallow the tablet whole as it is supplied. Patient information often advises that the tablets not be crushed, broken, or chewed unless a healthcare provider specifically directs otherwise.


Q: Does the time of day I take Pax matter?

Pax is often prescribed in divided doses throughout the day. Due to its common side effect of somnolence (drowsiness), the timing of doses is an element that may be considered in the overall administration plan.


Q: How long does it typically take for Pax to start working?

Pharmacokinetic data from regulatory documents indicate that after taking the tablet by mouth, the medication typically reaches its peak concentration in the bloodstream between 1 and 1.5 hours.


Q: If I miss a dose of Pax, what should I do?

General patient guidelines for missed doses advise that if it is almost time for the next scheduled dose, the missed dose should typically be skipped. The protocol typically states to continue with the regular schedule, and not to take two doses to make up for the missed one.


Q: How long does Pax stay in your system after the last dose?

Pax (Diazepam) is classified as a long-acting drug. Its elimination half-life is up to 48 hours, and its active metabolite can remain in the system with an even longer half-life, up to approximately 100 hours.


Q: Are there any reported interactions between Pax and herbal remedies?

Official guidance advises exercising caution with herbal products due to the potential for many to increase the effects of CNS depression (drowsiness or sedation). Specific regulatory information on all possible herbal remedies is not fully available in general patient documents.


Q: How is Pax supposed to be stored?

Official information mandates that Pax should be stored at controlled room temperature, typically between 20 C to 25 C (68 F to 77 F). The medication should also be protected from moisture and direct light.


Q: Does Pax expire, and is it still safe after the expiration date?

Like all regulated medicines, Pax is assigned a specific expiration date by the manufacturer, which is printed on the label. The label indicates the medication should not be used past this date, as the manufacturer cannot guarantee its potency and stability afterward.


Q: Is Pax available as a generic medicine?

Yes. The active ingredient in Pax, Diazepam, is widely available as an officially authorized generic medicine in many markets, according to regulatory public assessment reports.


Q: Why is Pax prescribed instead of other medicines sometimes?

The regulatory profile classifies Pax as a long-acting Benzodiazepine, which is a key pharmacological feature. This sustained effect is a feature noted in its classification which may be relevant to certain treatment needs.


Q: Do I need to change my diet while taking Pax?

Official labeling advises avoiding alcohol entirely and exercising caution with Grapefruit products due to known interactions that can increase the drug's effects. No other general dietary changes are typically specified in official documents.


Q: What is the typical duration of treatment with Pax?

Regulatory documents specify that for conditions such as anxiety symptoms, the duration of use should be short-term. Treatment should generally not exceed two to four weeks, a period which includes any necessary dose tapering.


Q: Are there different strengths of Pax tablets available?

Yes. The tablets containing the active ingredient Diazepam are officially manufactured and supplied in several different strengths. Common available strengths include 2 mg, 5 mg, and 10 mg tablets.


Q: Are there any studies looking at the long-term safety of Pax?

Official regulatory warnings highlight the risks of physical dependence and severe withdrawal symptoms associated with sustained, long-term use. This regulatory warning highlights the risks associated with long-term use, which must be considered in the overall safety profile.


Q: Does Pax show up on standard drug tests?

As a Benzodiazepine, the active ingredient in Pax and its associated metabolites can be detected in standard toxicology screening tests designed to identify this specific class of medications.

How should Pax be stored and disposed of?

Storage and Disposal Requirements

Official regulatory information mandates specific conditions for storing and disposing of Paxlovid to maintain its stability and ensure environmental safety.

Requirement Area Official Instructions
Storage Temperature Store at controlled room temperature, 20 C to 25 C (68 F to 77 F).
Packaging Keep the medicine in its original child-resistant blister card until the time of use.
Handling Store in a cool, dry place. Do not remove the tablets and store them in a different container.
Disposal Do not flush or dispose of in household waste.
Environmental Rule Dispose of all unused or expired medicine in accordance with local and federal pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Pax found in:

A-Z Index: